[go: up one dir, main page]

MX2020008120A - Metodos y composiciones para inhibir las actividades biologicas de adam9. - Google Patents

Metodos y composiciones para inhibir las actividades biologicas de adam9.

Info

Publication number
MX2020008120A
MX2020008120A MX2020008120A MX2020008120A MX2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A MX 2020008120 A MX2020008120 A MX 2020008120A
Authority
MX
Mexico
Prior art keywords
adam9
biological activities
methods
compositions
modulating peptides
Prior art date
Application number
MX2020008120A
Other languages
English (en)
Inventor
Marcia L Moss
Robert Rasmussen
Chris Price
Original Assignee
Verra Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics filed Critical Verra Therapeutics
Publication of MX2020008120A publication Critical patent/MX2020008120A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan péptidos moduladores de ADAM9 y métodos para usar los mismos para modular las actividades biológicas de ADAM9 in vitro y/o in vivo, para inhibir las actividades biológicas de ADAM9 asociadas con enfermedades o trastornos en los sujetos, para disminuir la inflamación, e inhibir la proliferación celular no deseada, la fibrosis, y la angiogénesis. En algunas realizaciones, los péptidos moduladores de ADAM9 incluyen modificaciones de uno o más aminoácidos de la secuencia de aminoácidos del prodominio de ADAM9 humano, y en algunas realizaciones, los péptidos moduladores de ADAM9 incluyen otras modificaciones tales como, pero sin limitación, la adición de grupos PEG.
MX2020008120A 2018-01-31 2019-01-31 Metodos y composiciones para inhibir las actividades biologicas de adam9. MX2020008120A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624491P 2018-01-31 2018-01-31
PCT/US2019/016015 WO2019152629A1 (en) 2018-01-31 2019-01-31 Methods and compositions for inhibiting adam 9 biological activities

Publications (1)

Publication Number Publication Date
MX2020008120A true MX2020008120A (es) 2020-09-18

Family

ID=67478593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008120A MX2020008120A (es) 2018-01-31 2019-01-31 Metodos y composiciones para inhibir las actividades biologicas de adam9.

Country Status (9)

Country Link
US (2) US12247232B2 (es)
EP (1) EP3746112A4 (es)
JP (2) JP2021512596A (es)
CN (1) CN113286606A (es)
AU (1) AU2019215009B2 (es)
CA (1) CA3094136A1 (es)
IL (1) IL276359B2 (es)
MX (1) MX2020008120A (es)
WO (1) WO2019152629A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3952973B1 (en) 2019-06-13 2023-06-07 Hollister Incorporated Reusable urinary catheter products
EP4628107A3 (en) 2019-06-25 2025-12-17 Hollister Incorporated Reusable urinary catheter products
US12329759B2 (en) * 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function
CA3195563A1 (en) * 2020-10-14 2022-04-21 Matteo Porotto Lipopeptide fusion inhibitors as sars-cov-2 antivirals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356877T1 (de) * 2000-07-28 2007-04-15 Immunex Corp Humane disintegrinproteine
US20040092466A1 (en) * 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of ADAM9 expression
WO2004024089A2 (en) 2002-09-11 2004-03-25 Sloan-Kettering Institute For Cancer Research Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
WO2004103390A2 (en) 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US7674619B2 (en) * 2005-02-02 2010-03-09 Mather Jennie P ADAM-9 modulators
CA2604883A1 (en) 2005-04-07 2006-10-19 Albert Lai Adam10 in cancer diagnosis, detection and treatment
WO2007143752A2 (en) * 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
US7638301B2 (en) 2006-08-28 2009-12-29 Biozyme, Inc. Prodomain modulators of ADAM 10
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
US20090285640A1 (en) 2008-05-16 2009-11-19 Hilfiker William K Method for constructing a mechanically stabilized earthen embankment using semi-extensible steel soil reinforcements
EP2534171A4 (en) 2010-02-11 2013-07-17 Univ Southern California MODIFIED ADAM DISINTEGRIN DOMAIN POLYPEPTIDES AND USES THEREOF
WO2012088105A2 (en) 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
US20190345473A1 (en) 2017-10-02 2019-11-14 Verra Therapeutics, Inc. Methods and compositions for inhibiting adam10 biological activities

Also Published As

Publication number Publication date
EP3746112A4 (en) 2021-10-20
IL276359B2 (en) 2025-01-01
JP2024170286A (ja) 2024-12-06
IL276359B1 (en) 2024-09-01
US20250188434A1 (en) 2025-06-12
CN113286606A (zh) 2021-08-20
US12247232B2 (en) 2025-03-11
US20190382745A1 (en) 2019-12-19
IL276359A (en) 2020-08-31
CA3094136A1 (en) 2019-08-08
EP3746112A1 (en) 2020-12-09
AU2019215009A1 (en) 2020-10-01
WO2019152629A1 (en) 2019-08-08
AU2019215009B2 (en) 2025-08-21
JP2021512596A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2020008120A (es) Metodos y composiciones para inhibir las actividades biologicas de adam9.
de Castro et al. Biologically active peptides: Processes for their generation, purification and identification and applications as natural additives in the food and pharmaceutical industries
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
ZA202002094B (en) Trispecific proteins and methods of use
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
WO2015183890A3 (en) Methods and compositions for the treatment of metabolic disorders and diseases
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
MX2013013833A (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas.
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
HK1214832A1 (zh) 用於代謝病症和疾病治療的組合物和方法
MX2022004345A (es) Construcciones de igf2 variantes.
MX388960B (es) Una población de células madre mesenquimales enriquecida en integrina a10alta y su uso en la prevención y tratamiento de daño o enfermedad ósea y cartílago.
EP4349361A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
EP4083058A3 (en) Delivery constructs for transcytosis and related methods
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
MY205028A (en) Protein for treatment of inflammatory diseases
MX2018011162A (es) Metodos de purificacion de colageno 7.
MX2020006971A (es) Variantes del peptido atf5 y usos de estas.
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
WO2019077634A3 (en) Therapeutic compositions of antimicrobial peptides
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
MY189759A (en) Conjugate of finasteride with peptide